uBriGene Biosciences Inc

uBriGene Biosciences is your bridge from ATMPs concept to commercialization. Our CDMO+ services include cell therapy products (CAR-T, TCR-T, NK Cells, iPSC, Dendritic cells, Macrophages), viral vectors (AAV, LVV, RVV, AdV, oncolytic viruses), plasmids, and RNA (mRNA, circRNA, acRNA). Our extensive experience in manufacturing, QC testing, and regulatory filing support of ATMPs, from early discovery to commercialization, will accelerate your therapeutic programs from bench to bedside. With four Centers of Excellence in North America, and Asia Pacific and more than 20 GMP clean room suites, uBriGene supports global CGT, vaccine, and RNA product development

Gene and cell,car-t,clinical applications,cro,cdmo,plasmids,viral vector,gene editing,mrna,and advanced therapy medicinal products

Ubrigene biosciences inc operates in the Biotechnology industry.

Ubrigene biosciences inc's revenue is 11m - 100m

Ubrigene biosciences inc has 11 - 50 employees.